Until the SRPT management announces the start of prospectively designed registration trial, Don't buy!!!
If the company is repeating the same story on 12 patient exploratory data adding the additional weeks of status, a big danger signal!!!
Only the start of registration trial will indicate that the company is confident that they can repeat the results seen in the current small exploratory trial in the registration trial!!! Something very fishy that they are not going beyond the 12 patient enrollment.....Whereas RNA/GSK is far ahead in their clinical development program which is vetted by the FDA.
It isn't a "level" but rather a time - better to wait. There is plenty of time on this one. Management has pushed the NDA filing to next year - first half. No need to buy before then.
What a d-bag you are coming here and asking that question, when many people here are losing their rear ends at this pps (on paper only, hopefully).
Do you mind I tell you to go eff off or something similar?
I bought some when it was $25 early this year.. then sold it when it went to$30 and I missed the boat to $40. Now looking to get back in. Not sure if it would come back to $25 or not but $30-$32 seems reasonable. I think but I'm not sure. Just wondering if some investors can share your thoughts? I'm only trade quarter by quarter.